Amedisys (AMED) Reports In-Line Q4 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% on concerns over AI buildout costs, Fed rate outlook
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil prices fall as investors focus on Hormuz flows after peace talks
- SpaceX slides, tech stocks dip — what’s moving markets
- Deutsche Bank cuts gold outlook as Fed repricing weighs on prices
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Amedisys Reports Fourth Quarter and Year End 2021 Financial Results; Issues 2022 Guidance
February 23, 2022 4:05 PM ESTBATON ROUGE, La., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three-month period and year ended December 31, 2021.
Three-Month Periods Ended December 31, 2021 and 2020
Net service revenue increased $8.6Â million to $559.3Â million compared to $550.7Â million in 2020.Net income attributable to Amedisys, Inc. of $34.0Â million compared to $45.2Â million in 2020.Net income attributable to Amedisys, Inc. per diluted share of $1.04 compared to $1.36 in 2020.Adjusted Quarterly Results*
Adjusted EBITDA of $64.8Â million compared to $78.1Â million in 2020.Adjusted net service revenue of $559.3Â million compared to $550.7Â million in... More